Table II.
pD2 and Emax
| A | Aorta | + NS398 | Aorta | |||
|---|---|---|---|---|---|---|
| pD2 | Emax | pD2 | Emax | |||
| Control | 7.01 ± 0.05 | 85.21 ± 2.01 | Control | 6.98 ± 0.07 | 79.7 0 ± 1.90 | |
| db−/db− | 7.22 ± 0.06 | 52.21 ± 1.01 | db−/db− | 7.19 ± 0.08 | 66.47 ± 1.46 | |
| db−/db− + DHMEQ | 7.21 ± 0.12 | 65.91 ± 3.60 | db−/db− + DHMEQ | 7.14 ± 0.08 | 81.03 ± 1.26 | |
| db−/db− + IKK-NBD peptide | 6.93 ± 0.06 | 66.81 ± 1.81 | db−/db− + IKK-NBD peptide | 7.02 ± 0.07 | 79.59 ± 1.63 | |
| db−/db-p-50NFkB-/- | 6.97 ± 0.08 | 92.19 ± 2.51 | db−/db-p-50NFkB-/- | 7.17 ± 0.12 | 85.52 ± 0.99 | |
| db−/db-PARP-1-/- | 7.45 ± 0.10 | 73.14 ± 1.17 | db−/db-PARP-1-/- | 7.10 ± 0.08 | 79.59 ± 1.67 | |
| B | + APO | Aorta | Aorta | |||
|---|---|---|---|---|---|---|
| pD2 | Emax | pD2 | Emax | |||
| Control | 7.41 ± 0.15 | 66.10 ± 4.07 | db−/db− | 7.31 ± 0.10 | 37.10 ± 1.07 | |
| db−/db− | 7.33 ± 0.16 | 47.57 ± 4.16 | db−/db− + AG1478 | 7.23 ± 0.09 | 54.75 ± 2.76 | |
| db−/db− + DHMEQ | 7.21 ± 0.02 | 61.13 ± 0.06 | db−/db− + P65 shRNA | 7.41 ± 0.12 | 66.00 ± 1.96 | |
| db−/db− + IKK-NBD peptide | 6.83 ± 0.09 | 63.59 ± 0.73 | db−/db− + Scramb | 7.86 ± 0.27 | 40.97 ± 0.54 | |
Data (means ± SE)
PD2 and Emax for thoracic aorta from control, type 2 diabetic mice (db−/db−) treated with and without DHMEQ or IKK-NBD peptide, double knockout mice db−/db-p50NFκB and double knockout db−/db-PARP-1 in the absence (A) or presence of apocynin (APO) (B) and COX-2 inhibitor (NS398) (C).
PD2 and Emax for thoracic aorta from type 2 diabetic mice (db−/db−) in vitro incubated with EGFRtk inhibitor (AG1478) or p65shRNA or scramble shRNA (D).